Clinical Trials

Study Title:
A Phase 2, Multicenter, Open label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First Line Treatment (CodeBreaK 201)

For more information about the trial above please contact the study team:

Principal Investigator, Mariam Alexander, at alexanma@musc.edu.

Study Coordinator, Alexandra Leitner, at leitnera@musc.edu, or please call +1 843-792-1507.

Trial opened at the following institutions: Medical University of South Carolina